Pay in 4 interest-free payments of $5.37 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
(AAOS Orthopaedic Sports Medicine) screened 544 peer-reviewed articles and identified 36 qualifying studies: 35 preclinical (rodent and dog models) and exactly 1 human trial
Half-life multiplied by 5-20 depending on parent peptide
Insurance almost never covers compounded peptide therapy, so these are cash-pay figures
PlexusDx Tirzepatide Injection ($289/mo) provides a compounded weekly injectable in the same active-ingredient family for cash-pay patients without insurance coverage for Zepbound or Mounjaro
A phase 2 trial conducted in the USA investigated the effect of weekly subcutaneous retatrutide at different doses and dose-escalations in participants with obesity and no diabetes [38]
US$ 26.19
US$ 26.66
US$ 24.30
